Antimalarial activity of amodiaquine-moxifloxacin: A study in mice.

Authors : Elias ADIKWU, Confidence Orgechi NWORGU, Simeon IGONO AJEKA

Pages : 1-6

Doi:10.47482/acmr.1140050

View : 12 | Download : 6

Publication Date : 2023-01-31

Article Type : Research Paper

Abstract :Background: The search for new partner drugs to increase the therapeutic activity of existing antimalarial drugs is important because of decreased Plasmodium susceptibility. Amodiaquine insert ignore into journalissuearticles values(AQ); is an antimalarial drug. Moxifloxacin insert ignore into journalissuearticles values(MX); is a fluoroquinolone antibiotic with promising antiplasmodial activity. This study evaluated the benefit of MX as a partner drug with AQ for malaria treatment in Plasmodium berghei-infected mice. Methods: Adult Swiss albino mice insert ignore into journalissuearticles values(28-35g); of both sexes, randomly grouped and inoculated with Plasmodium berghei were used. The mice were treated orally with AQ insert ignore into journalissuearticles values(10 mg/kg);, MX insert ignore into journalissuearticles values(6 mg/kg); and AQ-MX, respectively using the curative, prophylactic and suppressive protocols. Blood samples were collected and assessed for percentage parasitemia and hematological indices. Liver samples were assessed for histological changes. Mean survival time insert ignore into journalissuearticles values(MST); was observed in treated mice. Results: The curative, prophylactic and suppressive tests showed that AQ-MX decreased percentage parasitemia with difference observed at p<0.05 when compared to AQ or MX. In the curative test, AQ, MX and AQ-MX produced 70.9 %, 65. 0% and 90.6% parasitemia inhibitions, respectively whereas CQ insert ignore into journalissuearticles values(Standard); produced 87.9 % parasitemia inhibition. AQ-MX prolonged MST with difference observed at p<0.05 in the curative, prophylactic and suppressive tests when compared to AQ or MX. The restored hematological indices caused by AQ-MX were characterized by increased hemoglobin, red blood cells, and packed cell volume with decreased white blood cells observed at p<0.05 when compared to AQ or MX. AQ-MX eradicates liver merozoites. Conclusion: MX may be an effective partner drug with AQ for malaria treatment.
Keywords : Amodiaquine, moxifloxacin, Antimalaria, partner drug, Plasmodium, mice